GlassScriptPhysician profile
Joel H King
NPI 1508896507
$1,970.05
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,225 · 2020: $163 · 2021: $442 · 2022: $140.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $375.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $348.96 | 2019-2022 | |
| Allergan, INC. | $303.74 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $284.99 | 2019-2021 | |
| Abbvie INC. | $142.70 | 2021-2022 | |
| Livanova USA, INC. | $125.96 | 2021 | |
| Sunovion Pharmaceuticals INC. | $117.14 | 2019 | |
| Lundbeck LLC | $78.37 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $41.91 | 2019-2020 | |
| Aytu Biopharma, INC. | $40.93 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.36 | 2021 | |
| Owp Pharmaceuticals, INC. | $20.62 | 2021 | |
| Bausch Health US, LLC | $20.53 | 2019 | |
| Shire North American Group INC | $20.00 | 2019 | |
| Merck Sharp & Dohme LLC | $17.59 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.